Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome

Felix Wohlrab^{1

2}, Mailam Eltity^{1

2}, Friederike Ufer³, Friedemann Paul^{1

2

4}, Carmen Scheibenbogen⁵, Judith Bellmann-Strobl^{1

2}

Affiliations

¹ Experimental and Clinical Research Center, A Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
² Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Experimental and Clinical Research Center, Berlin, Germany.
³ Clinic for Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁴ NCRC-Neuroscience Clinical Research Center, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.
⁵ Institute of Medical Immunology, Charité - Universitätsmedizin, Berlin, Germany.

Editorial

Felix Wohlrab et al. Expert Opin Biol Ther. 2025 May.

. 2025 May;25(5):1-5.

doi: 10.1080/14712598.2025.2492774. Epub 2025 Apr 15.

Felix Wohlrab^{1

2}, Mailam Eltity^{1

2}, Friederike Ufer³, Friedemann Paul^{1

2

4}, Carmen Scheibenbogen⁵, Judith Bellmann-Strobl^{1

2}

¹ Experimental and Clinical Research Center, A Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
² Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Experimental and Clinical Research Center, Berlin, Germany.
³ Clinic for Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁴ NCRC-Neuroscience Clinical Research Center, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.
⁵ Institute of Medical Immunology, Charité - Universitätsmedizin, Berlin, Germany.

No abstract available

Keywords: AAb; ME/CFS; PCS; autoimmunity; biological therapies; long COVID; post-COVID syndrome; targeted therapies.

Publication types